Breaking Down Windtree Therapeutics, Inc. (WINT) Financial Health: Key Insights for Investors

Is Windtree Therapeutics, Inc. (WINT) poised for a turnaround, or are there financial headwinds on the horizon? As of December 31, 2024, the company's financial results reveal a net loss of $1.8 million, a significant improvement from the $20.3 million loss in 2023. But with research and development expenses climbing to $16.3 million and cash reserves standing at just $1.8 million, how long can Windtree sustain its operations, especially with funding expected to last only through April 2025?

Windtree Therapeutics, Inc. (WINT) Revenue Analysis

Windtree Therapeutics, Inc., a biotechnology company, focuses on developing and commercializing novel therapies for respiratory diseases and other unmet medical needs. Understanding the company's revenue streams involves examining its product sales, licensing agreements, and collaborations.

As of the fiscal year 2024, detailed information on Windtree Therapeutics' specific revenue breakdown is not readily available in the search results. Financial data, including revenue streams, growth rates, and segment contributions, are typically found in the company's annual reports (Form 10-K) and quarterly reports (Form 10-Q) filed with the Securities and Exchange Commission (SEC). These reports offer a comprehensive overview of the company's financial performance.

To gain insights into Windtree Therapeutics’ revenue, investors should consider the following:

• Product Sales: Analyze revenue generated from the sales of approved products, if any.
• Licensing Agreements: Evaluate income derived from licensing agreements, including upfront payments, milestone payments, and royalties.
• Collaborations and Grants: Assess revenue from research and development collaborations, as well as government grants.
• Year-over-Year Growth: Calculate the percentage increase or decrease in revenue compared to the previous year to identify growth trends.
• Segment Contribution: Determine how each business segment (e.g., different therapeutic areas) contributes to the overall revenue.

For more detailed information, refer to Windtree Therapeutics' official filings and investor presentations. These resources provide a comprehensive analysis of the company's financial health and revenue streams. Also, explore Mission Statement, Vision, & Core Values of Windtree Therapeutics, Inc. (WINT).

Windtree Therapeutics, Inc. (WINT) Profitability Metrics

Understanding Windtree Therapeutics, Inc.'s profitability involves examining several key financial metrics. These metrics provide insights into the company's ability to generate earnings relative to its revenue, operating costs, and invested capital. Let's delve into the details.

As of the fiscal year 2024, Windtree Therapeutics, Inc. has specific financial data that sheds light on its profitability:

• Gross Profit: Analyzing the gross profit helps to understand the direct costs associated with revenue generation.
• Operating Profit: Examining the operating profit margin reveals the efficiency of the company's operational activities.
• Net Profit: The net profit margin indicates the percentage of revenue remaining after all expenses, including taxes and interest, are accounted for.

To provide a clearer picture, here's a hypothetical snapshot of Windtree Therapeutics, Inc.'s profitability metrics based on the guidance for 2024 (Note: Since real-time financial data is dynamic and specific values aren't available, the following table uses illustrative figures):

Trends in Profitability Over Time

Observing trends in profitability over several periods can reveal whether Windtree Therapeutics, Inc. is improving its financial performance. An upward trend in gross, operating, and net profit margins suggests enhanced efficiency and cost management.

Comparison with Industry Averages

Comparing Windtree Therapeutics, Inc.'s profitability ratios with industry averages provides context. If the company's margins are lower than the industry average, it may indicate areas for improvement in cost control or pricing strategies. Conversely, higher margins could suggest a competitive advantage.

Analysis of Operational Efficiency

Operational efficiency is critical for profitability. Key areas to analyze include:

• Cost Management: Efficient cost management directly impacts the gross and operating profit margins. Lower production and operational costs can lead to higher profitability.
• Gross Margin Trends: Monitoring gross margin trends helps identify whether the company is effectively managing its direct costs of goods or services.

Exploring Windtree Therapeutics, Inc. (WINT) Investor Profile: Who’s Buying and Why?: Exploring Windtree Therapeutics, Inc. (WINT) Investor Profile: Who’s Buying and Why?

Windtree Therapeutics, Inc. (WINT) Debt vs. Equity Structure

Understanding how Windtree Therapeutics, Inc. (WINT) manages its debt and equity is crucial for investors. It sheds light on the company's financial strategy and risk profile. Let's delve into the specifics of their debt levels, ratios, and financing activities.

Based on the latest information, Windtree Therapeutics, Inc. (WINT) carries both short-term and long-term debt. While the specifics of these figures can fluctuate, examining their balance sheet provides a clearer picture. As of the end of the 2024 fiscal year, details about their debt structure is as follows:

• Short-Term Debt: Represents obligations due within a year.
• Long-Term Debt: Consists of obligations due beyond one year.

The company's approach to managing these debts impacts its financial stability and growth potential.

The debt-to-equity ratio is a key metric for assessing Windtree Therapeutics, Inc.'s (WINT) financial leverage. This ratio indicates the proportion of debt and equity the company uses to finance its assets. A higher ratio suggests greater financial risk, as the company relies more on debt. Here's how to interpret this ratio:

• Calculation: Total Liabilities divided by Total Equity.
• Interpretation: A ratio above 1.0 indicates that debt exceeds equity, while a ratio below 1.0 suggests the opposite.
• Industry Comparison: Comparing Windtree Therapeutics, Inc.’s (WINT) ratio to industry averages provides context on whether its leverage is typical or excessive.

Windtree Therapeutics, Inc. (WINT) periodically engages in debt issuances, credit rating assessments, and refinancing activities to optimize its capital structure. Recent activities may include:

• New Debt Issuances: Issuing bonds or taking out loans to raise capital.
• Credit Ratings: Assessments by rating agencies like Standard & Poor's or Moody's, influencing borrowing costs.
• Refinancing: Replacing existing debt with new debt, potentially at more favorable terms.

Balancing debt and equity is a strategic decision for Windtree Therapeutics, Inc. (WINT). Debt financing can provide capital for growth initiatives, but it also increases financial risk. Equity funding, on the other hand, dilutes ownership but strengthens the balance sheet. The company must carefully weigh these factors to achieve sustainable growth.

For those interested in understanding Windtree Therapeutics, Inc.'s (WINT) broader objectives, you might find this resource helpful: Mission Statement, Vision, & Core Values of Windtree Therapeutics, Inc. (WINT).

Windtree Therapeutics, Inc. (WINT) Liquidity and Solvency

Liquidity and solvency are critical indicators of a company's financial health, revealing its ability to meet short-term obligations and sustain long-term operations. For Windtree Therapeutics, Inc. (WINT), a thorough examination of these metrics provides valuable insights for investors.

Assessing Windtree Therapeutics, Inc.'s Liquidity:

Analyzing Windtree Therapeutics, Inc.'s liquidity involves examining key ratios and cash flow trends. These metrics help determine if the company has sufficient liquid assets to cover its immediate liabilities.

• Current and Quick Ratios: These ratios measure a company's ability to pay off short-term liabilities with its current assets. The current ratio is calculated by dividing current assets by current liabilities, while the quick ratio excludes inventory from current assets to provide a more conservative measure.
• Analysis of Working Capital Trends: Monitoring working capital, which is the difference between current assets and current liabilities, indicates whether a company is efficiently managing its short-term resources.
• Cash Flow Statements Overview: A review of cash flow statements, categorized into operating, investing, and financing activities, reveals how Windtree Therapeutics, Inc. (WINT) generates and uses cash. Trends in these areas can highlight potential liquidity issues or strengths.

Liquidity Positions: Current and Quick Ratios

The current ratio and quick ratio are fundamental metrics for assessing Windtree Therapeutics, Inc.'s (WINT) short-term liquidity. A current ratio of 1.0 or higher generally indicates that a company has enough current assets to cover its current liabilities. The quick ratio, which excludes inventories, provides a more stringent assessment of liquidity.

Working Capital Trends

Monitoring Windtree Therapeutics, Inc.'s working capital trends over time can reveal significant insights into its operational efficiency and short-term financial health. Consistent growth in working capital suggests effective management of current assets and liabilities, whereas a decline may signal potential challenges in meeting short-term obligations.

Cash Flow Statements Overview

An overview of Windtree Therapeutics, Inc.'s cash flow statements provides a comprehensive understanding of its liquidity. The cash flow statement is divided into three main sections:

• Operating Activities: This section shows the cash generated or used from the company's core business operations. Positive cash flow from operations indicates that the company is generating sufficient cash from its primary activities.
• Investing Activities: This includes cash flow from the purchase and sale of long-term assets, such as property, plant, and equipment (PP&E).
• Financing Activities: This section reflects cash flow from activities related to debt, equity, and dividends.

Potential Liquidity Concerns or Strengths

Based on the analysis of current and quick ratios, working capital trends, and cash flow statements, potential liquidity concerns or strengths can be identified. For instance, a declining current ratio coupled with negative cash flow from operations might raise concerns about the company's ability to meet its short-term obligations. Conversely, a rising current ratio and positive cash flow from operations could indicate a strong liquidity position.

For additional insights into Windtree Therapeutics, Inc. (WINT) and its investors, check out: Exploring Windtree Therapeutics, Inc. (WINT) Investor Profile: Who’s Buying and Why?

Windtree Therapeutics, Inc. (WINT) Valuation Analysis

Determining whether Windtree Therapeutics, Inc. (WINT) is overvalued or undervalued requires an examination of several key financial metrics and market indicators. These include price-to-earnings (P/E), price-to-book (P/B), and enterprise value-to-EBITDA (EV/EBITDA) ratios, as well as stock price trends, dividend information (if applicable), and analyst consensus.

Currently, Windtree Therapeutics does not have a P/E ratio because the company has negative earnings. As of February 14, 2025, Windtree Therapeutics had a Price/Book ratio of 2.18. This metric compares a company's market capitalization to its book value of equity, providing insight into how the market values the company's net assets.

Analyzing Windtree Therapeutics' stock price trends over the past year provides context on market sentiment and investor confidence. As of April 2025, the stock has shown considerable volatility. Recent data indicates:

• Today's Change: -3.85%
• 1 Week Change: -1.27%
• 1 Month Change: -30.00%
• Year to Date (YTD) Change: -51.43%

Given that Windtree Therapeutics does not currently offer dividends, dividend yield and payout ratios are not applicable. For companies in the biotechnology sector, this is not unusual as they often prioritize reinvesting earnings into research and development.

Here’s a snapshot of WINT's stock performance:

For a deeper dive into the investors behind Windtree Therapeutics, explore this related article: Exploring Windtree Therapeutics, Inc. (WINT) Investor Profile: Who’s Buying and Why?

Windtree Therapeutics, Inc. (WINT) Risk Factors

Windtree Therapeutics, Inc. (WINT) faces a variety of risks that could significantly impact its financial health. These risks span internal operational challenges and external market dynamics, including industry competition, regulatory changes, and overall market conditions. Understanding these factors is crucial for investors assessing the company's long-term viability.

Here's an overview of key risks:

• Industry Competition: The biotechnology industry is intensely competitive. Windtree faces competition from larger pharmaceutical companies with greater resources, potentially affecting their ability to successfully commercialize their products.
• Regulatory Changes: The development and commercialization of Windtree's products are subject to extensive regulation by health authorities like the FDA. Changes in regulatory policies or delays in approvals can significantly impact timelines and increase costs.
• Market Conditions: Unfavorable market conditions, including economic downturns or shifts in investor sentiment towards the biotechnology sector, can affect Windtree's ability to raise capital and maintain its stock value.

Operational, financial, and strategic risks are often detailed in Windtree's earnings reports and filings. These may include:

• Clinical Trial Risks: The success of Windtree depends heavily on the outcomes of its clinical trials. Unfavorable results, delays, or the inability to enroll patients can significantly impede progress and impact the company’s valuation.
• Funding and Liquidity Risks: As a development-stage company, Windtree requires substantial capital to fund its operations. The inability to secure additional funding through equity offerings, debt financing, or partnerships could jeopardize its ability to continue operations.
• Commercialization Risks: Even if Windtree successfully develops and gains regulatory approval for its products, there is no guarantee they will be commercially successful. Market acceptance, pricing pressures, and competition from other therapies can affect sales and profitability.

Mitigation strategies or plans, if available, are important for investors to consider. These strategies might include:

• Diversification of Pipeline: Developing multiple product candidates can reduce the risk associated with the failure of any single program.
• Strategic Partnerships: Collaborating with larger pharmaceutical companies can provide financial support and expertise in development and commercialization.
• Efficient Resource Management: Implementing cost-effective strategies and managing resources efficiently can help extend the company's cash runway.

Investors can gain further insights into Windtree Therapeutics, Inc. (WINT) by reviewing an investor profile: Exploring Windtree Therapeutics, Inc. (WINT) Investor Profile: Who’s Buying and Why?

Windtree Therapeutics, Inc. (WINT) Growth Opportunities

Windtree Therapeutics, Inc. is focused on developing innovative therapies to address significant unmet medical needs in respiratory disease and other areas. Future growth prospects hinge on several key factors, including product innovation, strategic partnerships, and competitive advantages.

Key Growth Drivers:

• Product Innovation: Windtree's pipeline focuses on respiratory therapies, particularly for acute respiratory distress syndrome (ARDS) and related conditions. Successful development and commercialization of these therapies are critical for future growth.
• Market Expansion: Expanding the indications for existing products and entering new geographic markets can significantly increase revenue streams.
• Strategic Partnerships: Collaborations with other pharmaceutical companies or research institutions can accelerate the development and commercialization of Windtree's products.

To understand where Windtree Therapeutics is headed, it's important to consider their strategic vision. Learn more about their goals here: Mission Statement, Vision, & Core Values of Windtree Therapeutics, Inc. (WINT).

While specific revenue growth projections and earnings estimates for Windtree Therapeutics beyond available data are speculative, understanding the company's recent financial performance and strategic initiatives provides a basis for assessing its potential.

Strategic Initiatives and Partnerships:

Windtree's future growth is closely tied to its ongoing clinical trials and regulatory approvals. Any strategic alliances or partnerships formed to enhance product development or market access will also play a crucial role.

Competitive Advantages:

Windtree Therapeutics operates in a competitive pharmaceutical landscape. The company's competitive advantages may include:

• Proprietary Technology: Unique drug delivery systems or formulations that enhance the efficacy or safety of its therapies.
• Orphan Drug Designations: If applicable, these designations can provide market exclusivity and other benefits for drugs targeting rare diseases.
• Strong Intellectual Property: Patents and other intellectual property rights that protect its products and technologies.

The following table summarizes potential growth drivers and considerations for Windtree Therapeutics: